When dual-combinations of covalent immunochemotherapeutics like gemcitabine-(C4-amide)-[anti-EGFR] and epirubicin-(C3-amide)-[anti-HER2/neu] are selectively “targeted” in-vivo at EGFR and HER2/neu that are highly over-expressed by chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) it results in initiation of several innate immune responses that produce a variable degree of anti-neoplastic cytotoxicity. The gene discussed is ERBB2; the disease is breast adenocarcinoma.